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LETTER TO THE EDITOR
Ototoxicity of cisplatinum
Sir - Skinner et al., in a recent article (1990) 61: 927-931,
concerning ototoxicity of cisplatinum in children and adole-
scents make a number of points which we would like to
comment on.
The authors take significant hearing loss to be a deteriora-
tion in hearing threshold of 20 decibels or greater at any
frequency. We would consider this to be a significant change
in hearing, but not to be equivalent to a significant hearing
loss. We were surprised that a difference was made in the
change in hearing threshold between younger (40dB) and
older children (20dB). A change of hearing threshold of
15 dB or more should be considered significant in the clinical
setting at any age over 7-8 months. Perhaps the authors
have confused the 40 dB cut-off used in the grading system
which is of clinical importance, and infers hearing loss and
disability, with that of a significant change in hearing.
The statistical analysis made by Skinner et al. uses maxi-
mum hearing loss which they define as being the maximum
loss in the right ear plus that in the left, divided by two. This
method makes the results worse than they actually are in
terms of hearing disability. The more standard method of
assessment used by the British Society of Audiology is the
standard weighted average hearing threshold which is: (4 x
the loss in the better ear + 1 x the loss in the worse ear)/5.
The plateau effect that Skinner et al. found at 8000 Hz
with a cumulative cisplatinum dose of 600 mgm-2 is interest-
ing but may be misleading. We would disagree about it being
of clinical importance and if we look at our group of 29
children (in press) in the same way there is no plateau. We
would suggest that in a small group of patients, where wide
individual susceptibility is apparent, the median bears little
relevance to the clinical situation in any one child. As an
example, 7 of the 29 patients in our group had received a
cumulative dose of cisplatinum of 600 mgm-2 and their
hearing loss at 8000 Hz (mean of the right and left ear) was
0.0, 7.5, 32.5, 62.5, 70, 72.5 and 87.5 with a median of 62.5.
The authors go on to discuss partial recovery of hearing
loss. In seven patients, with high-frequency hearing loss of
grade two or more, that we have followed up with multiple
audiograms for at least 5 years, we have seen no recovery.
The example of partial recovery shown by the authors uses
results obtained at a frequency of 8000 Hz. This is the most
difficult reading to obtain accurately, it needs to be calibrated
more carefully and regularly than the other frequencies and
children give more accurate results in the middle frequencies.
The authors then state that severe hearing loss can be
asymptomatic and that there is no relation between our
ototoxicity grading and the presence or absence of symp-
toms. To justify this statement Skinner et al. would have to
have applied a recognised hearing disability questionnaire or
made an objective measurement of speech discrimination
levels. From the article this does not appear to have been
done. In our experience, severe high-frequency hearing loss is
always symptomatic if the child is fully assessed. However
mild to moderate high-frequency hearing loss is not always
immediately recognised by the patient, parent or school-
teacher. The child unconciously learns to lip read and it may
be some time later before the child starts to fall behind at
school and the degree of handicap and need for hearing aids
are appreciated.
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